Impact of and polymorphisms on heart rate of post-PCI patients treated with metoprolol.

To explore the effect of (100C > T) and 1165 G > C polymorphisms on heart rate of post-PCI (percutaneous coronary intervention) patients treated with metoprolol succinate sustained-release tablets. A total of 756 inpatients with metoprolol succinate sustained-release tablets were selected and the genotypes of and 1165G > C were detected in 319 patients using gene chip detection. The target heart rate was defined as a resting heart rate < 70 beats/min. Clinical data were collected. A total of 319 inpatients were enrolled in the study. The mutant allele frequencies of and were 57.21 and 69.44%, respectively. Whatever the dose of metoprolol, the heart rates were lower in patients with homozygous mutation of than those with heterozygous mutation and wild-type (p < 0.05). Nevertheless, this effect was not seen between different genotypes of . Logistic regression analysis showed that the dose of metoprolol and the genotypes of were predictors of heart rate <70 beats/min in these patients. Further multivariate analysis indicated that patients with homozygous mutation had better control of heart rates compared with those with wild-type and heterozygous mutation of genotypes (all: p < 0.001). polymorphisms were associated with the heart rate of post-PCI patients treated with metoprolol succinate sustained-release tablets.